Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy

British Journal of Clinical Pharmacology

Volumn 48, Issue 1, 1999, Pages 63-70

  Vadher, B D ^a,c   Patterson, D L H ^a   Leaning, M ^b  

^a WHITTINGTON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

Anticoagulation; Bayesian; Computer; Decision support; Initiation; Warfarin

Indexed keywords

HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BAYES THEOREM; COMPUTER ANALYSIS; CONTROLLED STUDY; ERROR; FEMALE; HEPARINIZATION; HUMAN; INTERNATIONAL STANDARD UNIT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PRIORITY JOURNAL;

ADULT; AGED; ANTICOAGULANTS; BAYES THEOREM; COMPUTER SIMULATION; DECISION MAKING, COMPUTER-ASSISTED; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; WARFARIN;

EID: 0033026079     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00967.x     Document Type: Article

References (41)

1. 1 Doble N, Baron JH. Anticoagulation control with warfarin by junior doctors. J Royal Soc Med 1987; 80: 627.
2. 2 Tan G, Cohen H, Taylor F, Gabbay J. Audit of start of anticoagulation treatment in inpatients. J Clin Pathol 1993; 46: 67-71.
3. 3 Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin-understanding the dose-effect relationship. Clin Pharmacokinet 1986; 11: 483-504.
4. 4 Landefeld CS, Bleyth RJ. Anticoagulant related bleeding: Clinical Epidemiology, Prediction, and Prevention. Am J Med 1993; 95: 315-328.
5. 5 Routledge PA, Chapman PH, Davies DM, Rawlins MD. Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmacol 1979; 8: 243-247.
6. 6 Weiss P, Halkin H, Almong S. The negative impact of biological variation in the effect and clearance of warfarin on methods for prediction of dose requirements. Thromb Haemost 1986; 56: 371-375.
7. 7 Fennerty A, Dolben J, Thomas P, Backhouse G, Bentley DP, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J 1984; 288: 1268-1270.
8. 8 Thompson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992; 22: 447-467.
9. 9 Svec JM, Coleman RW, Mungall DR, Ludden TM. Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation. Ther Drug Monit 1985; 7: 174-180.
10. 10 Boyle DA, Ludden TM, Carter BL, Becker AJ, Taylor JW. Evaluation of a Bayesian regression program for predicting warfarin response. Ther Drug Monit 1989; 11: 276-284.
11. 11 Loeliger EA. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost 1985; 54: 155-156.
12. 12 McKernan A, Thomson JM, Poller L. The reliability of INRs during short term anticoagulant treatment Clin Lab Haematol 1988; 10: 63-71.
13. 13 Drugs and Therapeutics Bulletin. How to Anticoagulate 1992; 30: 77-80.
14. 14 British Society for Haematology, British Committee for Standards in Haematology, Haemostasis and Thrombosis Task Force. Guidelines on Oral Anticoagulation, 3rd edn. Br J Haematol 1998; 101: 374-387.
15. 15 Andreasen P, Vessell E. Comparison of plasma levels of antipyrine, tolbutamide and warfarin after oral and intravenous administration. Clin Pharmacol Ther 1974; 16: 1059-1065.
16. 16 Brozovic M. Investigation of Haemostasis. In: Practical Haematology eds Dacie, JV Lewis, SM London: Churchill Livingstone, 1991: 267-277.
17. 17 Leaning MS, Boroujerdi MA. A system for compartmental modelling and simulation. Comput Meth Programs Biomed 1991; 35: 71-92.
18. 18 Chan E, Aarons L, Serlin M, Breckenridge A, Rowland M. Inter-relationship among individual vitamin K-dependent factors at different levels of anticoagulation. Br J Clin Pharmacol 1987; 24: 621-625.
19. 19 Paul B, Oxley Brigham K, Cox T, Hamilton PJ. Factor II, VII, IX and X concentrations in patients receiving long term warfarin. J Clin Pathol 1986; 40: 84-88.
20. 20 Kumar S, Haigh JRM, Tate G et al. Effect of warfarin on plasma concentrations of vitamin K dependent coagulation factors in patients with stable control and monitored compliance. Br J Haematol 1990; 74: 82-85.
21. 21 Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6: 429-453.
22. 22 Stirling Y, Howarth DJ, Stocley R, Bland R, Towler CM, Harding SM. Comparison of the bioavailabilites and anticoagulant activities of two warfarin formulations Br J Haematol 1982; 51: 37-46.
23. 23 Weiss P, Soff GA, Halkin H, Seligsohn U. Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb Res 1987; 45: 783-790.
24. 24 Talstad I. Which coagulation factors interfere with the one-stage PT? Haemost 1993; 23: 19-25.
25. 25 Burns ER, Goldberg SN, Wenz B. Paradoxic effect of multiple mild coagulation factor deficiencies on the prothrombin time and activated partial thromboplastin time. Am J Clin Pathol 1993; 100: 94-98.
26. 26 Sheiner LB, Beal SL. Bayesian individualisation of pharmacokinetics: Simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982; 71: 1344-1348.
27. 27 Bentley DP, Backhouse G, Hutchings A, Haddon RL, Spragg B, Routledge PA. Investigation of patients with abnormal response to warfarin. Br J Clin Pharmacol 1986; 22: 37-41.
28. 28 Microsoft. Excel, Version, 4.0 Users guide. Redmond, CA. Microsoft Corp. 1991.
29. 29 British National Formulary. Joint publication of the British Medical Association and the Royal Pharmaceutical Society of Great Britain. 1995 Vol. 30.
30. 30 British Society for Haematology, British Committee for Standardsin Haematology, Haemostasis and Thrombosis Task Force. Guidelines on oral anticoagulation, 2nd edn. J Clin Pathol 1990; 43: 177-183.
31. 31 Carter BL, Barr W, Rock W, Taylor JW. Warfarin dosage predictions assisted by analogue computer. Ther Drug Monit 1988; 10: 69-73.
32. 32 Sun I, Chang MW. Initialization of warfarin dosages using computer modelling. Arch Phys Med Rehabil 1995; 76: 453-456.
33. 33 White RH, Vennok AP, Murray W, Coleman RW. Initiation of warfarin therapy: Comparison of Physician dosing with computer-assisted dosing. J Gen Int Med 1987; 2: 141-148.
34. 34 Poller L. The effect of the use of different tissue extracts on one-stage prothrombin times. Acta Haematol 1964; 32: 292-298.
35. 35 Zucker S, Brosious E, Cooper JR. One-stage prothrombin time survey. Am J Clin Pathol 1970; 53: 340-347.
36. 36 Schulz NJ, Slaker RA, Rosborough TK. The influence of heparin on the prothrombin time. Pharacother 1991; 11: 312-316.
37. 37 Sheiner LB, Rosenburg B, Marathe V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445-457.
38. 38 Mungall DR, Ludden TM, Marshall J, Hawkins DW, Talbert RL, Crawford MH. Population pharmacokinetics of racemic warfarin in adult patients. J Pharmacokinet Biopharm 1985; 13: 213-227.
39. 39 Wells PS, Holbrook AM, Crowther NR, Hirsch J. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 678-693.
40. 40 Fihn SD, McDonell MB, Vermes D, et al. A computerized intervention to improve timing of out-patient follow up: a multicenter randomised trial in patients treated with warfarin. National Consortium of Anticoagulant clinics. J Gen Intern Med 1994; 9: 131-139.
41. 41 Vadher B, Patterson DLH, Leaning M. Evaluation of a decision-aid for initiation and control of oral anticoagulation in a prospective controlled trial. Br Med J 1997; 314: 1252-1256.